News

Paris-based Exhalon will receive $1 million to evaluate the potential of a non-invasive test that uses volatile organic compounds in exhaled breath to indicate the presence of an LRTI. By turning a patient's single breath into a diagnostic, we aim to demonstrate that the real time analysis of volatile organic compounds in exhaled breath can transform the management of respiratory infections, supporting faster, better-targeted decisions and strengthening antibiotic stewardship worldwide," Stanislas Grassin Delyle, PharmD, principal investigator at Exhalon, said in a CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) press release. Working with researchers at Imperial College London, the company will evaluate RNA biomarkers of the body's immune response to infection, with the aim of translating them into gene-based assays that can deliver quick results in emergency and remote-care settings. "Rapid, reliable diagnostics are essential to ensuring that children with lower-respiratory tract infections receive the right treatment quickly, while also helping to reduce the misuse of antibiotics," said Richard Alm, PhD, interim chief of research and development at CARB-X."